Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- 30 September 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 14 (10), 933-942
- https://doi.org/10.1016/s1470-2045(13)70335-8
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancerBritish Journal of Cancer, 2013
- Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysisAnnals of Oncology, 2012
- Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trialBreast Cancer Research and Treatment, 2012
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast CancerThe New England Journal of Medicine, 2012
- 803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC)European Journal of Cancer, 2011
- Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?Journal of Clinical Oncology, 2011
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08Journal of Clinical Oncology, 2011
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerThe New England Journal of Medicine, 2007
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995